Dove Mild Cleanser
PreclinicalSmall molecule
Dove Mild Cleanser is one of 7 small molecule programs targeting Tolerance. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
9 competitors in Tolerance
#DrugCompanyPhaseTrials
1Avigan
AAppili Therapeutics Inc.
Phase 2
Experimental
BiogenPreclinical
Levo-Dromoran
VValeant Pharmaceuticals
Preclinical
Siplizumab
UUniversity of Alabama at Birmingham
Preclinical
Oxytocin Treatment
UUniversity of Electronic Science and Technology of China
Preclinical
Tazorac
FFougera Pharmaceuticals Inc.
Preclinical
Dove Mild Cleanser
UUniversity of Michigan
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Dove Mild Cleanser. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of Michigan